ScholarDeck

Randomized trialNature medicine · 2026

Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.

Deborah A Theodore, Bryan T Mayer, Charlotte-Paige Rolle … Magdalena E Sobieszczyk

Infectious DiseaseRandomized trial

Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.

Deborah A Theodore et al. · Nature medicine · 2026

Background

Broadly neutralizing antibodies (bnAbs) are a promising tool for HIV prevention and treatment.

Methods

In arms 1-3 were not randomized.

Results

this percentage of participants experienced fatigue, the most common side effect

More results

54 participants living with HIV (PLWH) or without HIV (PLWoH) received 10E8.4/iMab or placebo.

In arm 1, PLWoH received 10E8.4/iMab 0.3 mg kg -1 IV, 1 mg kg -1 SC, or 1 mg kg -1 IV (n = 3 each).

In arm 2, PLWoH received 10E8.4/iMab 3 mg kg -1 IV, 10 mg kg -1 IV or 30 mg kg -1 IV (n = 6 each).

More results

In arms 3/3a, PLWH received 10E8.4/iMab 10 mg kg -1 IV (n = 3) or 30 mg kg -1 IV (n = 6).

“

Conclusion

These data support further study of 10E8.4/iMab to expand HIV treatment and prevention options.